El inhibidor de la JAK, CP-690,550 (tofacitinib), inhibe la expresión de quimiocinas inducida por TNF en los sinoviocitos fibroblásticos: papel autocrino del interferón de tipo I
Annals of Rheumatic Diseases 2012; 71:440-47
This study investigated the effect of the novel Janus kinase (JAK) inhibitor CP-690,550 [tofacitinib] in fibroblast-like synoviocytes (FLSs) collected from patients with rheumatoid arthritis (RA). Human FLSs were cultured from the synovial tissue of patients with RA who were undergoing arthroplastic surgery, cultured and then serum-starved 48 hours prior to stimulation. Quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) or multiplex bead assay were used to...